A new AHA scientific statement warns that cardiovascular disease is rising fastest among younger women, with stroke rates in ...

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Joint AASLD/IDSA practice recommendations reflect new data on prevention, treatment, and surveillance of chronic hepatitis B, ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms ...

A peer navigator intervention following a nonfatal opioid overdose in the emergency department does not significantly reduce ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.

Chronic kidney disease is associated with a significantly increased risk for workforce detachment among adults of working age, a Danish study finds.

Thirty years after its discovery, scientists are eyeing leptin with renewed interest, for everything from weight loss drug ...

Walk-in appointments can reduce the time to pediatric dermatology visits for both atopic dermatitis and hidradenitis suppurativa and reduce ED visits for atopic dermatitis, a study finds.